Inflammation-dependent cerebral deposition of serum amyloid A protein in a mouse model of amyloidosis

Journal of Neuroscience

Volumn 22, Issue 14, 2002, Pages 5900-5909

  Guo, Jun tao ^a   Yu, Jin ^a   Grass, David ^d   De Beer, Frederick C ^b   Kindy, Mark S ^a,c,e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

^d Xenogen Corporation   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimer's disease; Cytokines; Indomethacin; Inflammation; Microglia; Serum amyloid A; Transgenic

Indexed keywords

INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SERUM AMYLOID A;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MOLECULAR MECHANICS; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 0037101616     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-14-05900.2002     Document Type: Article

References (58)

1. Abraham CR, Slekoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501.
2. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M (1982) Further characterization of amyloid-enhancing factor. Lab Invest 47:139-146.
3. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 285:111-114.
4. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158:63-73.
5. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188:431-438.
6. Breitner JC (1996) The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 47:401-411.
7. Burgermeister P, Calhoun ME, Winkler DT, Jucker M (2000) Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann NY Acad Sci 903:307-316.
8. Calhoun ME, Burgermeister P, Phinney AL, Stadler M, Tolnay M, Wiederhold K-H, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96:14088-14093.
9. Cotman CW, Tenner AJ, Cummings BJ (1996) β-amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging 17:723-731.
10. Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (Berl) 57:239-242.
11. Fishkin RJ, Winslow JT (1997) Endotoxin-induced reduction of social investigation by mice: Interaction with amphetamine and anti-inflammatory drugs. Psychopharmacology 132:335-341.
12. Friman C, Pettersson T (1996) Amyloidosis. Curr Opin Rheumatol 8:62-71.
13. Gahtan E, Overmier JB (1999) Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequelae. Neurosci Biobehav Rev 23:615-633.
14. Galimberti D, Baron P, Meda L, Prat E, Scarpini E, Delgado R, Catania A, Lipton JM, Scarlato G (1999) Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. Biochem Biophys Res Commun 263:251-256.
15. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Duido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
16. Ganowiak K, Hultman P, Engstrom U, Gustavsson A, Westermark P (1994) Fibrils from synthetic amyloid-related peptides enhance development of experimental AA amyloidosis in mice. Biochem Biophys Res Commun 199:306-312.
17. Gatti S, Bartfai T (1993) Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: Comparison with interleukin-1 family and interleukin-6. Brain Res 624:291-294.
18. Griffin WS, Stanley LC, Ling C, White L, Macleod V, Perrot LJ, White CL, Arora C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611-7615.
19. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B (1994) Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 35:598-607.
20. Hoffman JS, Ericsson LH, Eriksen N (1984) Murine tissue amyloid protein AA. J Exp Med 159:641-646.
21. Hogan B, Costantini F, Lacy E (1982) Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
22. Howland DS, Hemmendinger JS, Carroll PD, Estes PS, Melloni Jr RH, DeGennaro LJ (1991) Positive- and negative-acting promoter sequences regulate cell type-specific expression of the rat synapsin I gene. Mol Brain Res 11:345-353.
23. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233.
24. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 274:177-178.
25. Kindy MS, de Beer FC (1999) A mouse model for serum amyloid A amyloidosis. Methods Enzymol 309:701-716.
26. Kindy MS, Rader DJ (1998) Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol 152:1387-1395.
27. Kindy MS, McCormack JE, Buckler AJ, Levine RA, Sonenshien GE (1987) Independent regulation of transcription of the two strands of the c-myc gene. Mol Cell Biol 7:2857-2862.
28. Kindy MS, King AR, Perry G, deBeer MC, deBeer FC (1995) Association of apolipoprotein E with murine amyloid A protein amyloid. Lab Invest 73:469-475.
29. Kindy MS, Yu J, Guo J, Zhu H (1999) Apolipoprotein serum amyloid A in Alzheimer's disease. J Alz Dis 1:155-167.
30. Liang J, Sloane JA, Wells JM, Abraham CR, Fine RE, Sipe JD (1997) Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci Lett 225:73-76.
31. Lim GP, Yang F, Chen P, Beech W, Teter B, Tran T, Ubeda O, Hsiao-Ashe K, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
32. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV (1998) Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 70:210-215.
33. McAdam KP, Sipe JD (1976) Murine model for human secondary amyloidosis: Genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med 144:1121-1127.
34. McGeer PL, McGeer EG (1998) Mechanisms of cell death in Alzheimer's disease: Immunopathology. J Neural Transm Suppl 54:1131-1137.
35. McGeer PL, Schulzer M, McGeer EG (1995) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 95:425-432.
36. Meek RL, Benditt EP (1986) Amyloid a gene family expression in different mouse tissues. J Exp Med 164:2006-2017.
37. Meek RL, Hoffman JS, Benditt EP (1986) Amyloidogenesis: One serum amyloid A isotype is selectively removed from the circulation. J Exp Med 163:499-510.
38. Natte R, de Boer WI, Maat-Schieman ML, Baelde HJ, Vinters HV, Roos RA, van Duinen SG (1999) Amyloid beta precursor protein-mRNA is expressed throughout cerebral vessel walls. Brain Res 828:179-183.
39. Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M (2000) Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 21:183-197.
40. Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ (1997) Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood brain barrier. Neurobiol Dis 4:27-34.
41. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I (1992) Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 92:10016-10020.
42. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM (2000) Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology 55:947-951.
43. Selkoe D (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17:489-517.
44. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
45. Shiroo M, Kawahara E, Nakanishi I, Migita S (1987) Specific deposition of serum amyloid A protein 2 in the mouse. Scand J Immunol 26:709-716.
46. Sipe JD (1992) Amyloidosis. Annu Rev Biochem 61:947-975.
47. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer's transgenic mice is associated with oxidative stress. J Neurochem 70:2212-2215.
48. Smith MA, Rottkamp CA, Numomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502:139-144.
49. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G (1994) Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 92:2016-2020.
50. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287-13292.
51. Tehranian R, Hasanvan H, Iverfeldt K, Post C, Schultzberg M (2001) Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett 301:54-58.
52. Vandenabeele P, Fiers W (1991) Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6 mediated "acute phase response" in the brain? Immunol Today 12:217-219.
53. Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F (2000) Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol 157:1283-1298.
54. Westermark GT, Engstrom U, Westermark P (1992) The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Com 182:27-33.
55. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M (2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21:1619-1627.
56. Yamamoto K, Shiroo M, Migita S (1986) Diverse gene expression for isotypes of murine serum amyloid A protein during acute phase reaction. Science 232:227-229.
57. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
58. Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921-932.